Clinical Recognition, Diagnostic Workup, Evidence-Based Management,and Functional Medicine Considerations

Yoon Hang Kim, MD, MPH

Board-Certified, Preventive MedicineIntegrative & Functional Medicine

Table of Contents

Introduction

Vitamin B6, a collective term encompassing pyridoxine, pyridoxal, and pyridoxamine and their phosphorylated derivatives, plays an indispensable role in human biochemistry. As the active coenzyme pyridoxal-5′-phosphate (PLP), it participates in over 140 enzymatic reactions spanning amino acid metabolism, neurotransmitter synthesis, heme biosynthesis, gluconeogenesis, and immune modulation. Given its centrality to so many physiologic pathways, it is perhaps unsurprising that vitamin B6 supplements are among the most widely consumed nutritional products worldwide.

What is surprising—and remains underrecognized even among seasoned clinicians—is that chronic supplementation with pyridoxine at doses many patients and practitioners still consider “safe” can produce a debilitating, sensory-predominant peripheral neuropathy. The hallmark clinical picture is a stocking–glove sensory neuropathy with proprioceptive loss, sensory ataxia, and, in severe cases, profound functional impairment—all with relatively preserved motor strength. This constellation, while first described in the medical literature decades ago, continues to be missed or misattributed to other causes such as diabetic neuropathy, B12 deficiency, or idiopathic polyneuropathy.

This chapter provides a comprehensive, clinically oriented review of vitamin B6 toxicity. It covers the clinical presentation, pathophysiology, dose–response relationships, diagnostic workup, conventional management, and—importantly for the integrative clinician—functional medicine considerations for supporting nerve recovery and preventing recurrence. The goal is to equip the reader with a practical framework for recognizing, evaluating, and managing this condition in real-world clinical practice.

Epidemiology and Dose–Response Relationships

Historical Context and Evolving Dose Thresholds

The neurotoxicity of high-dose pyridoxine was first clearly documented in the early 1980s, when Schaumburg and colleagues described a severe sensory neuropathy in patients consuming megadoses exceeding 2,000 mg per day. For many years afterward, clinical teaching centered on a reassuring narrative: that B6 toxicity was essentially a phenomenon of extreme megadosing, and that intakes below 500 mg daily posed negligible risk.

That narrative has been steadily revised. Accumulating case reports and case series over the past two decades have demonstrated neuropathy at chronic intakes as low as 100 mg per day, and occasionally even lower in susceptible individuals. This evolving evidence base prompted a landmark regulatory revision in 2023, when the European Food Safety Authority (EFSA) lowered the tolerable upper intake level (UL) for adults from 25 mg per day to just 12 mg per day—a dramatic acknowledgment that the safety margin for supplemental pyridoxine is far narrower than previously believed.

In contrast, the United States National Institutes of Health (NIH) and many supplement labels continue to reference a UL of 100 mg per day, a figure that many clinicians and patients interpret as a blanket safety threshold. This regulatory lag creates a practical hazard: patients who diligently “stay under the limit” at 50–80 mg daily may still be accumulating a toxic burden, particularly over months or years of consistent use.

Common Sources of Excessive Intake

A critical step in clinical evaluation is recognizing the numerous and often overlapping sources of supplemental B6 that patients may be consuming. These include:

• Standalone pyridoxine supplements (commonly sold as 50–100 mg tablets)
• B-complex formulations, many of which contain 25–100 mg of B6 per serving
• “Energy,” “nerve support,” “methylation,” and “adrenal” formulas that include B6 as a secondary ingredient
• PMS, migraine, and carpal tunnel products, which historically included high-dose B6 based on older clinical data
• Fortified foods, protein powders, meal replacements, and energy drinks, which can contribute meaningful amounts when combined with supplement use

It is not uncommon to discover, upon careful inventory, that a patient consuming what they believe to be a single “reasonable” B-complex is actually ingesting 75–150 mg of total B6 per day from stacked sources.

Individual Susceptibility

Not every patient with elevated B6 intake develops toxicity. Interindividual variation in pyridoxal kinase (PDXK) activity, hepatic metabolic capacity, and possibly genetic polymorphisms in B6-handling enzymes likely contributes to the wide range of susceptibility observed clinically. Duration of exposure is a critical modifying factor: because pyridoxine can accumulate in tissues over weeks to months, even moderate daily doses may eventually saturate metabolic pathways and produce toxicity in patients who have been supplementing for prolonged periods.

Clinical Presentation

Core Neurologic Features

The clinical signature of B6 toxicity is a sensory-predominant peripheral neuropathy, often with features that distinguish it from the more familiar motor-sensory neuropathies encountered in general practice. Understanding this pattern is essential for timely recognition.

Sensory Symptoms

The earliest and most consistent complaints are bilateral numbness, tingling, burning, and “pins and needles” sensations beginning in the distal lower extremities. These symptoms typically follow a stocking distribution, ascending from the toes and feet toward the ankles and lower legs. In more severe or prolonged cases, the hands become involved, producing the classic stocking–glove pattern. Patients may describe a sensation of walking on cotton or sand, or a feeling that their feet are “not their own.”

Proprioceptive and Vibratory Loss

A hallmark feature—and one that should strongly raise clinical suspicion—is impaired proprioception (position sense) and vibratory perception. Patients may be unable to reliably identify the position of their toes or fingers with eyes closed. This proprioceptive deficit produces sensory ataxia: a wide-based, unsteady gait that worsens in the dark or when visual input is removed (positive Romberg sign). Falls and near-falls are common presenting concerns.

Reflex Changes

Deep tendon reflexes are typically diminished or absent at the ankles, and may be reduced at the knees in more advanced cases. The areflexia is consistent with large-fiber sensory neuronopathy affecting the dorsal root ganglia.

Preserved Motor Function

Unlike many other peripheral neuropathies—and this is a crucial clinical clue—motor strength is usually relatively or completely preserved. A patient who presents with significant sensory loss, ataxia, and areflexia but maintains normal grip strength and lower extremity power should prompt the clinician to think beyond the usual differential and consider B6 toxicity, among other sensory neuronopathies.

Pain and Dysesthesia

Neuropathic pain is variable but can be prominent. Patients may describe burning, electric-shock sensations, or allodynia (pain from normally non-painful stimuli such as bedsheets touching the feet). Lhermitte-like phenomena—electric-shock sensations radiating down the spine or limbs with neck flexion—have been reported, likely reflecting dorsal column involvement.

Non-Neurologic and Associated Features

Anecdotal reports describe mood changes, cognitive fog, and emotional lability in association with B6 toxicity. While these are plausible given B6’s role in neurotransmitter synthesis (including serotonin, dopamine, and GABA), the strongest and most reproducible evidence supports a sensory neuronopathy as the primary clinical manifestation. Non-neurologic symptoms should be evaluated carefully but not accepted uncritically as evidence of B6 toxicity in isolation.

It is worth noting that patients are frequently misdiagnosed before the correct etiology is identified. Common misattributions include diabetic neuropathy (even in non-diabetics), B12 deficiency, chronic inflammatory demyelinating polyneuropathy (CIDP), and idiopathic sensory polyneuropathy. A careful supplement history often resolves the diagnostic uncertainty.

Pathophysiology

The mechanisms by which excess pyridoxine produces sensory nerve injury are not fully elucidated, but converging lines of evidence support several interrelated hypotheses. These are worth understanding in some depth, because they inform clinical decision-making around B6 form, dose, and repletion strategy.

Hepatic Metabolic Saturation

Under normal conditions, ingested pyridoxine is phosphorylated to pyridoxine-5′-phosphate (PNP) in the gut and liver, then oxidized to PLP by pyridox(am)ine-5′-phosphate oxidase. When intake exceeds the capacity of these enzymatic pathways, unconverted pyridoxine and its metabolites accumulate in the circulation and tissues, reaching concentrations that become directly neurotoxic.

Pyridoxal Kinase Inhibition

One of the more compelling mechanistic hypotheses involves the paradoxical inhibition of pyridoxal kinase (PDXK) by excess pyridoxine. PDXK is the enzyme responsible for phosphorylating pyridoxal to PLP within neurons. In vitro and experimental data suggest that when pyridoxine concentrations are pathologically elevated, the excess substrate may competitively inhibit PDXK’s ability to generate PLP from pyridoxal, creating a functional PLP deficit at the very site where it is most needed. This proposed “local deficiency amid systemic excess” model offers a plausible explanation for a clinical puzzle that has long confused practitioners: why patients with elevated serum B6 levels can paradoxically exhibit signs and symptoms that overlap with B6 deficiency. If the model is correct, the neuron is, in effect, starving for active coenzyme despite being awash in precursor.

If intraneuronal PLP depletion occurs as proposed, downstream consequences would include impaired GABAergic neurotransmission, which may contribute to neuronal excitotoxicity and accelerate sensory neuron degeneration.

Dorsal Root Ganglia Injury

Experimental and neuropathologic data consistently demonstrate that the primary site of injury in B6 toxicity is the dorsal root ganglion (DRG). Large sensory neurons within the DRG are selectively vulnerable, and their degeneration accounts for the clinical pattern of large-fiber sensory loss (proprioception, vibration) with relative sparing of motor function. Degeneration of the central projections of DRG neurons into the dorsal columns of the spinal cord further explains the proprioceptive loss, sensory ataxia, and Lhermitte-like phenomena observed in affected patients.

Because DRG neurons are part of the peripheral nervous system and lie outside the blood–brain barrier, they are particularly exposed to circulating toxins—including excess pyridoxine—without the protection afforded to central neurons.

Diagnostic Workup

The diagnosis of B6 toxicity is fundamentally clinical, resting on the combination of a compatible neurologic presentation and a credible exposure history. Laboratory testing and neurophysiology serve to support the diagnosis, quantify severity, and exclude alternative etiologies.

Step 1: Detailed Supplement and Medication History

This is the single most important diagnostic step and the one most frequently omitted. The clinician should systematically document every source of B6 in the patient’s regimen:

• All vitamins, multivitamins, and B-complex products
• Standalone B6 supplements
• Combination products marketed for energy, mood, nerve health, methylation support, adrenal function, PMS, migraines, or homocysteine reduction
• Protein powders, meal replacements, energy drinks, and fortified foods
• Prescription medications containing pyridoxine (e.g., some isoniazid co-formulations)

For each product, the clinician should record the B6 dose per serving and the duration of use in months or years. A total daily B6 intake should be calculated by summing all sources.

Step 2: Laboratory Testing

The following laboratory panel is recommended for suspected B6 toxicity:

In inflammatory states, red-cell PLP may more accurately reflect tissue status than plasma PLP alone.

Step 3: Neurologic Examination

A focused sensory-motor examination should assess:

• Sensory modalities: pinprick, temperature, light touch, vibration (tuning fork), and proprioception (joint position sense)
• Deep tendon reflexes: ankle jerks, knee jerks
• Gait and coordination: Romberg test, tandem gait
• Motor strength: manual muscle testing of distal and proximal muscle groups

The typical examination in B6 toxicity reveals diminished distal sensory perception (particularly vibration and proprioception), reduced or absent ankle reflexes, a positive Romberg sign, and preserved or near-normal motor strength.

Step 4: Neurophysiologic Testing

Nerve conduction studies (NCS) and electromyography (EMG) are not required for diagnosis when the clinical picture and exposure history are clear, but they are valuable in atypical or uncertain cases and for documenting baseline severity.

The characteristic electrodiagnostic pattern in B6 toxicity is a sensory-predominant axonal neuropathy: reduced amplitudes or absent sensory nerve action potentials (SNAPs) with relatively preserved compound muscle action potentials (CMAPs) and motor conduction velocities. This pattern distinguishes B6 toxicity from demyelinating neuropathies and primarily motor neuropathies.

In atypical cases, referral to neurology for additional evaluation—including small-fiber neuropathy testing (skin biopsy for intraepidermal nerve fiber density), autoimmune panels, or paraneoplastic workup—may be warranted.

Step 5: Follow-Up Testing

B6 levels should be rechecked approximately 4–6 weeks after cessation of all pyridoxine-containing products. Declining levels confirm the exposure was exogenous and help correlate the laboratory trajectory with the patient’s clinical course.

Conventional Management

Immediate Discontinuation of All B6-Containing Products

This is the only definitive disease-modifying intervention. All supplements, products, and medications containing any form of vitamin B6 should be immediately discontinued. The clinician should specifically educate patients to identify B6 on labels under all of its common names: pyridoxine, pyridoxine hydrochloride (HCl), pyridoxal-5′-phosphate (P5P), pyridoxamine, and simply “vitamin B6.”

There is no role for forced diuresis, dialysis, chelation, or any active elimination strategy. Vitamin B6 is water-soluble and is cleared naturally once exogenous intake ceases.

Symptomatic Treatment of Neuropathic Pain

When neuropathic pain is clinically significant, treatment follows established neuropathic pain guidelines:

Adjunctive measures including sleep optimization, physical therapy for balance and fall prevention, and gait training should not be overlooked; they are often as important as pharmacotherapy in improving functional outcomes.

Prognosis and Recovery

Recovery from B6 neuropathy is typically slow, unfolding over months to years. The degree of recovery correlates with the duration and magnitude of the toxic exposure. Patients identified early—particularly those with mild or moderate symptoms and shorter exposure histories—have the best prospects for meaningful or complete recovery. In contrast, patients with long-standing, high-dose exposure may experience incomplete recovery, with residual sensory deficits and neuropathic symptoms persisting indefinitely.

Setting realistic expectations at the outset is essential. Patients should understand that nerve repair is a biological process measured in months, not days, and that symptom improvement may be gradual and nonlinear.

Functional Medicine Considerations

For the integrative and functional medicine practitioner, the management of B6 toxicity extends beyond simply stopping the offending supplement and prescribing gabapentin. The functional approach seeks to address the full landscape of the problem: removing the toxic exposure comprehensively, supporting the biology of nerve repair, optimizing nutritional cofactors, and—critically—understanding the clinical logic that led to the excessive supplementation in the first place, so that it is not repeated.

Comprehensive Exposure Audit

A thorough supplement inventory is the foundation of functional management. This goes beyond simply asking “Are you taking B6?” and requires a product-by-product review of every supplement, functional food, protein powder, and fortified product in the patient’s daily regimen. The total daily B6 load should be calculated and documented. In the author’s experience, most patients are genuinely surprised to discover how much B6 they have been consuming when all sources are tallied; the cumulative intake frequently exceeds 50–100 mg per day from stacked products.

Nutritional Status and Cofactor Optimization

Because B6 does not operate in isolation, and because patients who supplement heavily with B6 often have broader nutritional concerns, a comprehensive nutritional assessment is warranted. Particular attention should be given to:

• B12, folate, riboflavin (B2), thiamine (B1), and niacin (B3): These vitamins are interconnected in methylation, homocysteine metabolism, and nerve maintenance. Deficiencies in any of them can independently produce or worsen neuropathy.
• Magnesium, zinc, and copper: These minerals are commonly found in the same combination products that contain high-dose B6. Imbalances—particularly copper deficiency—can produce or exacerbate neuropathy.
• Vitamin E and omega-3 fatty acids: Both play roles in membrane integrity and nerve cell health.

When B6 repletion is genuinely needed for clinical indications (and it sometimes is), dietary sources—poultry, fish, organ meats, legumes, whole grains, and bananas—should be preferred over supplementation unless a documented deficiency demands otherwise.

Pyridoxine Versus Pyridoxal-5′-Phosphate (P5P): A Nuanced Discussion

A question that arises frequently in functional medicine practice is whether the active coenzyme form, pyridoxal-5′-phosphate (P5P), is “safer” than pyridoxine. The theoretical basis for this idea is that P5P bypasses the hepatic conversion steps that can become saturated with pyridoxine, thereby reducing the risk of toxic accumulation.

In practice, the picture is more nuanced. While most reported cases of B6 neuropathy involve pyridoxine, toxicity has been documented with high-dose P5P as well, albeit less frequently. The PDXK inhibition model further complicates this question: if excess pyridoxine impairs the neuron’s ability to handle any form of B6, then switching to P5P at equivalent doses may not fully eliminate risk.

The practical recommendation for patients with a history of B6 neuropathy is straightforward: avoid high-dose B6 supplementation in any form. If repletion is medically necessary, use the lowest effective dose—often 10–25 mg per day or less—and monitor both symptoms and serum levels closely.

Supporting Nerve Repair and Mitigating Oxidative Stress

Although the evidence base for nerve-restorative nutraceuticals is stronger in other neuropathy etiologies (particularly diabetic neuropathy) than in B6-specific toxicity, functional protocols commonly include agents with plausible mechanisms and reasonable safety profiles:

• Alpha-lipoic acid (ALA): A potent antioxidant studied in diabetic neuropathy (the NATHAN 1 trial showed improvement in some secondary neuropathy impairment measures, though the primary composite endpoint was not significant), with a theoretical role in supporting mitochondrial function and nerve metabolism.
• Acetyl-L-carnitine: Has been studied for neuropathic pain reduction and nerve fiber regeneration.
• Omega-3 fatty acids (EPA/DHA): Anti-inflammatory and supportive of neuronal membrane integrity.
• Curcumin, resveratrol, and N-acetylcysteine (NAC): Provide antioxidant and anti-inflammatory support, though direct evidence in B6 neuropathy is limited.
• Vitamin D optimization: Low vitamin D status has been associated with worse neuropathic pain outcomes in multiple cohorts.

Lifestyle interventions—including adequate sleep, stress management, and gentle movement practices such as walking, tai chi, or similar balance-oriented exercises—support neuroplasticity, proprioceptive retraining, and overall recovery. These should be considered integral components of the treatment plan, not afterthoughts.

Methylation and Genetic Context

A common clinical scenario in functional medicine is the patient who has been prescribed high-dose B6 for “methylation support,” often in the context of MTHFR polymorphisms or elevated homocysteine. While B6 is indeed a cofactor in the transsulfuration pathway and plays a legitimate role in homocysteine metabolism, the empiric use of high-dose B6 for this indication deserves reconsideration in light of the toxicity data.

A more targeted approach uses laboratory guidance—serum homocysteine, B12, folate, and PLP levels—to determine whether B6 supplementation is actually needed, and if so, at what dose. In patients with a history of B6 neuropathy, alternative strategies for homocysteine reduction should be prioritized:

• 5-methyltetrahydrofolate (5-MTHF) as the active folate form
• Methylcobalamin and/or adenosylcobalamin as active B12 forms
• Riboflavin (B2), which is a cofactor for MTHFR itself
• Lifestyle modifications: dietary quality, regular exercise, smoking cessation

This approach respects the biochemistry while avoiding the risk of re-injury from high-dose B6.

The Theoretical Role of Low-Dose Naltrexone in B6-Induced Neuropathy: A Clinical Hypothesis

Author’s Note: The following section represents the author’s clinical hypothesis and observations drawn from over a decade of experience prescribing low-dose naltrexone (LDN) across a broad range of neuroimmune and pain conditions, including authorship of the LDN Primer and LDN for Clinicians. It is presented as a theoretical framework grounded in known pharmacology and clinical pattern recognition—not as evidence from randomized controlled trials of LDN in B6-specific neuropathy, which do not yet exist. It is offered to stimulate clinical thinking and future investigation.

Rationale: Why LDN Deserves Consideration in Toxic Neuropathy

The conventional management of B6 toxicity—cessation of the offending supplement and symptomatic treatment with gabapentinoids or duloxetine—addresses the exposure and the pain but does little to actively modulate the neuroinflammatory milieu that may perpetuate nerve injury even after B6 levels have normalized. This gap in the treatment paradigm is where LDN becomes theoretically relevant.

LDN operates through two primary pharmacologic mechanisms that are directly germane to the pathophysiology of toxic neuropathy. First, transient blockade of mu-opioid receptors triggers a compensatory upregulation of endogenous opioid production—including beta-endorphin and met-enkephalin—that enhances the body’s intrinsic analgesic and anti-inflammatory capacity. Second, and perhaps more importantly for this context, LDN antagonizes Toll-like receptor 4 (TLR4) on activated microglia, dampening the release of proinflammatory cytokines (TNF-α, IL-1β, IL-6) that drive neuroinflammation and central sensitization.

In B6 toxicity, the primary site of injury is the dorsal root ganglion (DRG)—a structure that sits outside the blood–brain barrier and is therefore exposed to both circulating toxins and immune mediators. It is reasonable to hypothesize that microglial activation and neuroinflammatory signaling, once initiated by pyridoxine-mediated neurotoxicity, may persist beyond the clearance of the offending agent, contributing to the slow and sometimes incomplete recovery that characterizes this condition. If this hypothesis is correct, then modulating microglial activity with LDN could theoretically shorten the recovery window or reduce the severity of residual symptoms.

Clinical Observations: LDN in Neuropathic Pain Populations

While no published trial has specifically examined LDN in B6-induced neuropathy, the available clinical data in adjacent neuropathic conditions is encouraging. A randomized, double-blind crossover trial comparing LDN (starting at 2 mg with titration up to 4 mg) to amitriptyline in painful diabetic neuropathy found similar analgesic outcomes with fewer reported adverse events in the LDN arm. A case series from a tertiary pain center reported that patients with neuropathic pain—including complex regional pain syndrome—were significantly more likely to respond to LDN than those with mechanical or structural pain conditions such as spondylosis, suggesting that LDN’s mechanism may be preferentially effective when neuroinflammation is a dominant driver.

In the author’s clinical experience, LDN has demonstrated consistent benefit in patients with neuropathic pain from various etiologies, including small fiber neuropathy, post-viral neuropathy, and neuropathy associated with dysautonomia and mast cell activation syndrome (MCAS). These are conditions in which neuroinflammation, TLR4-mediated immune activation, and endorphin dysregulation overlap—precisely the mechanistic landscape that characterizes the aftermath of B6 toxicity.

Dose-Dependent Responses and Clinical Nuance

A critical clinical observation, drawn from the author’s prescribing experience and teaching through the LDN Support Group, is that dose-dependent responses in neuropathy are nonlinear and highly individualized. A patient may experience substantial neuropathy improvement at a dose as low as 0.5 mg of LDN within two weeks, yet upon titrating upward to 0.75 mg, develop symptoms of nervous system overstimulation—heightened sound sensitivity, internal restlessness, and physiologic manifestations of anxiety.

This pattern is not a side effect in the conventional sense; it reflects the interplay between endorphin rebound dynamics and a nervous system that is already sensitized. In patients recovering from B6 neurotoxicity, where dorsal root ganglia are actively regenerating and sensory circuits are in a state of heightened plasticity, this dose sensitivity is expected to be even more pronounced. The clinical implication is that LDN dosing in this population should begin at microgram-level doses (0.25–0.5 mg) and be titrated with exceptional patience, guided by symptom response rather than any standard protocol.

The optimal dose for pain relief may differ from the dose that best supports fatigue resolution or mood stabilization. This observation—that different symptoms have different dose–response curves within the same patient—is a key teaching point that the author has emphasized in both the LDN Primer and clinical practice.

The Endorphin Depletion Consideration

An additional consideration specific to B6 toxicity is the potential interaction between pyridoxine-induced neuronal injury and the endogenous opioid system. PLP is a cofactor for the decarboxylase enzymes involved in neurotransmitter synthesis, and its functional depletion in DRG neurons—the paradox described earlier in this chapter, where neurons starve for active coenzyme despite circulating excess—may impair endogenous opioid peptide production at the very sites where pain modulation is most needed.

If B6 toxicity creates a state of localized endorphin depletion through impaired neurotransmitter biosynthesis, then LDN’s ability to stimulate compensatory endorphin upregulation becomes doubly relevant: it addresses not only the neuroinflammatory component of the injury but also the neurotransmitter deficit that may be uniquely prominent in this toxicity. This is speculative but mechanistically coherent, and it represents a hypothesis worthy of formal investigation.

Practical Framework for LDN Use in B6-Induced Neuropathy

Based on the author’s clinical experience with LDN across neuropathic pain populations and the mechanistic rationale outlined above, the following practical framework is proposed for clinicians considering LDN as adjunctive therapy in patients recovering from B6 toxicity:

• Timing: Initiate LDN only after all B6-containing supplements have been discontinued and B6 levels are trending downward. LDN is not a substitute for removing the toxic exposure; it is an adjunct aimed at modulating the neuroinflammatory aftermath.
• Starting dose: Begin at 0.25–0.5 mg at bedtime. Patients with histories of chemical sensitivity, MCAS, or severe neuropathy may require compounded doses as low as 0.1 mg.
• Titration: Increase by 0.25–0.5 mg every 2–4 weeks, guided by symptom response. The goal is the lowest dose that provides meaningful symptom improvement. Many neuropathy patients stabilize at 1.5–3.0 mg; doses above 4.5 mg are rarely indicated.
• Monitoring: Track neuropathic pain severity, proprioceptive function, gait stability, and sleep quality. The emergence of vivid dreams, mild insomnia, or transient worsening of symptoms at a new dose level is common and usually resolves within 1–2 weeks; if not, reduce the dose.
• Combination context: LDN should be integrated into the broader functional medicine framework described in this chapter—alongside cofactor optimization, nerve-supportive nutraceuticals (alpha-lipoic acid, acetyl-L-carnitine), and lifestyle measures. LDN is most powerful when it is one layer in a comprehensive, multimodal strategy.
• Contraindications: LDN is contraindicated in patients currently using opioid medications or opioid-containing analgesics. It should be used with caution in patients with hepatic impairment. LDN is off-label for all indications discussed here and requires informed consent and individualized prescribing.

A Call for Investigation

The absence of randomized controlled trial data for LDN in B6-specific neuropathy is not evidence of absence of effect—it reflects the practical reality that toxic neuropathies are rarely studied as standalone entities in pharmacotherapy trials, and that LDN research has historically been underfunded relative to its clinical adoption. The mechanistic rationale is strong, the safety profile is favorable, the adjacent clinical evidence in diabetic and other neuropathies is encouraging, and the clinical observations in integrative practice are consistent. What is needed now is formal investigation: prospective case series, objective neurophysiologic endpoints (nerve conduction studies, intraepidermal nerve fiber density), and patient-reported outcome measures tracked over the months-long recovery trajectory of B6 neuropathy.

Until such data exist, the framework presented here should be regarded as a clinical hypothesis offered in the spirit of advancing the conversation—not as a treatment guideline. It is the author’s hope that this chapter contributes to that conversation and that future investigators will bring the rigor of formal study to a question that patients are already asking in practice.

Patient Education and Prevention

Effective prevention rests on patient education—a domain where clinicians can have disproportionate impact. Patients should be taught to:

• Read supplement labels carefully and identify all forms of B6 (pyridoxine, pyridoxine HCl, P5P, pyridoxamine, “vitamin B6”)
• Avoid stacking multiple products containing B6 without calculating the cumulative dose
• Recognize early neuropathy symptoms—tingling, numbness, unsteadiness—and report them promptly rather than attributing them to aging or other causes
• Understand that “more is not better” with water-soluble vitamins, and that the water-soluble designation does not guarantee safety at any dose

For patients who require ongoing B6 supplementation for legitimate medical indications (such as isoniazid therapy or documented deficiency states with specific metabolic needs), the clinician should prescribe the lowest effective dose and establish a schedule for periodic symptom reassessment and level monitoring.

Practical Clinical Algorithm

The following stepwise approach summarizes the evaluation and management of suspected B6 toxicity:

• Step 1 – Clinical Suspicion: Suspect B6 toxicity in any patient presenting with new or progressive sensory neuropathy (particularly stocking–glove distribution, proprioceptive loss, or sensory ataxia) who has any history of B-complex, multivitamin, “nerve,” “energy,” or high-dose vitamin use.
• Step 2 – Exposure History: Obtain a detailed supplement and medication inventory. Calculate total daily B6 intake from all sources.
• Step 3 – Laboratory Evaluation: Order plasma PLP (± total B6/pyridoxine), B12, folate, vitamin E, comprehensive metabolic panel, HbA1c, and TSH.
• Step 4 – Neurologic Assessment: Perform a focused sensory-motor examination. Consider NCS/EMG if diagnosis is uncertain or to establish baseline severity.
• Step 5 – Immediate Intervention: Discontinue all B6-containing products. Educate the patient on hidden sources.
• Step 6 – Symptom Management: Treat neuropathic pain with gabapentinoids, duloxetine, or other agents as clinically appropriate.
• Step 7 – Nerve Support: Optimize nutritional status, lifestyle factors, and consider evidence-informed nutraceuticals. Avoid re-exposure to high-dose B6 in any form.
• Step 8 – Follow-Up: Recheck B6 levels at 4–6 weeks. Monitor clinical trajectory over months, with the understanding that recovery is gradual.

Conclusion

Vitamin B6 toxicity represents a clinically important and preventable cause of sensory neuropathy that remains underrecognized in both conventional and integrative practice. The toxicity threshold is lower than most clinicians and patients appreciate, and the consequences of delayed diagnosis can be significant and long-lasting.

The integrative clinician is uniquely positioned to address this condition comprehensively: not merely by stopping the offending supplement, but by understanding why the patient was taking it in the first place, conducting a thorough exposure audit, supporting the biology of nerve repair through evidence-informed nutritional and lifestyle strategies, and educating the patient to prevent recurrence. In doing so, we honor the central tenet of integrative medicine: treating the whole patient, not just the presenting symptom.

As the regulatory landscape continues to evolve—with the EFSA’s 2023 revision to a 12 mg/day UL signaling a paradigm shift in how we define “safe” B6 intake—clinicians must stay current and counsel patients accordingly. The era of casually prescribing 100 mg of pyridoxine should be behind us.

References

1.  Schaumburg H, Kaplan J, Windebank A, et al. Sensory neuropathy from pyridoxine abuse: a new megavitamin syndrome. N Engl J Med. 1983;309(8):445–448.

2.  Dalton K, Dalton MJT. Characteristics of pyridoxine overdose neuropathy syndrome. Acta Neurol Scand. 1987;76(1):8–11.

3.  EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA). Scientific opinion on the tolerable upper intake level for vitamin B6. EFSA J. 2023;21(5):8006. doi:10.2903/j.efsa.2023.8006.

4.  National Institutes of Health, Office of Dietary Supplements. Vitamin B6 Fact Sheet for Health Professionals. Updated June 16, 2023.

5.  Merck Manual Professional Edition. Vitamin B6 Toxicity. Accessed 2025.

6.  Health Sciences Authority (Singapore). High-dose vitamin B6 and risk of peripheral neuropathy. Published May 15, 2023.

7.  Healthdirect (Australian Government). Vitamin B6 toxicity. Accessed 2025.

8.  Abosamak NER, Rout P. Vitamin B6 (Pyridoxine). In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026. Updated June 19, 2026.

9.  Ghavanini AA, Kimpinski K. Revisiting the evidence for neuropathy caused by pyridoxine deficiency and excess. J Clin Neuromuscul Dis. 2014;16(1):25–31. doi:10.1097/CND.0000000000000049.

10. Vrolijk MF, Opperhuizen A, Jansen EH, et al. The vitamin B6 paradox: supplementation with high concentrations of pyridoxine leads to decreased vitamin B6 function. Toxicol In Vitro. 2017;44:206–212.

11. Hadtstein F, Vrolijk MF. Vitamin B6-induced neuropathy: exploring the mechanisms of pyridoxine toxicity. Adv Nutr. 2021;12(5):1911–1929.

12. Bender DA. Non-nutritional uses of vitamin B6. Br J Nutr. 1999;81(1):7–20.

13. Finnerup NB, Attal N, Haroutounian S, et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol. 2015;14(2):162–173.

14. Ziegler D, Low PA, Litchy WJ, et al. Efficacy and safety of antioxidant treatment with alpha-lipoic acid over 4 years in diabetic polyneuropathy: the NATHAN 1 trial. Diabetes Care. 2011;34(9):2054–2060.

15. Di Stefano G, Di Lionardo A, Galosi E, et al. Acetyl-L-carnitine in painful peripheral neuropathy: a systematic review. J Pain Res. 2019;12:1341–1351.

16. Younger J, Parkitny L, McLain D. The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain. Clin Rheumatol. 2014;33(4):451–459.

17. Srinivasan A, Dutta P, Bansal D, Chakrabarti A, Bhansali AK, Hota D. Efficacy and safety of low-dose naltrexone in painful diabetic neuropathy: a randomized, double-blind, active-control, crossover clinical trial. J Diabetes. 2021;13(10):770–778. doi:10.1111/1753-0407.13202.

18. McKenzie-Brown AM, Boorman DW, Ibanez KR, Agwu E, Singh V. Low-dose naltrexone (LDN) for chronic pain at a single institution: a case series. J Pain Res. 2023;16:1993–1998. doi:10.2147/JPR.S389957.

19. Kim YH. LDN, emotional distress, neuropathy, chronic fatigue syndrome, and mitochondrial support. IFM Synergy [blog]. March 14, 2026. Available at: https://www.ifmsynergy.com/ldn-emotional-distress-neuropathy-chronic-fatigue-syndrome-and-mitochondrial-support/

20. Kim YH. The endorphin depletion hypothesis in CFS/ME. IFM Synergy [blog]. February 24, 2026. Available at: https://www.ifmsynergy.com/the-endorphin-depletion-hypothesis-in-cfs-me/

21. Kim YH. Low dose naltrexone (LDN) in functional medicine: a practical guide by Dr. Yoon Hang Kim in San Antonio. IFM Synergy [blog]. May 2, 2026. Available at: https://www.ifmsynergy.com/low-dose-naltrexone-ldn-in-functional-medicine-a-practical-guide-by-dr-yoon-hang-kim-in-san-antonio/

22. Kim YH. MCAS: a new epidemic in plain sight. IFM Synergy [blog]. May 26, 2026. Available at: https://www.ifmsynergy.com/mcas-a-new-epidemic-in-plain-sight/

23. Zagon IS, McLaughlin PJ. Naltrexone modulates tumor response in mice with neuroblastoma. Science. 1983;221(4611):671–673.

24. Brown N, Panksepp J. Low-dose naltrexone for disease prevention and quality of life. Med Hypotheses. 2009;72(3):333–337.